Department of Nursing, Pomeranian Medical University in Szczecin, 71-210 Szczecin, Poland.
Department of History of Medicine and Medical Ethics, Pomeranian Medical University in Szczecin, 70-205 Szczecin, Poland.
Int J Environ Res Public Health. 2022 Aug 24;19(17):10516. doi: 10.3390/ijerph191710516.
The aim of this study was to evaluate the influence of β-endorphins and serotonin on the course of treatment, disease-free time, and overall survival of patients with ovarian cancer. This study may contribute to the identification of modifiable factors that may influence the treatment of ovarian cancer. The research was carried out in a group of 162 patients of which 139 respondents were included in the research; ovarian cancer was diagnosed in 78 of these patients. The study consisted of three stages. In the first stage of diagnostics, a survey among the patients was carried out. In the second stage-5 mL of blood was collected from each patient ( = 139) in the preoperative period to determine the concentration of β-endorphin and serotonin. In the third stage-blood samples were collected from those patients who had completed chemotherapy treatment or had surgery. Concentrations of β-endorphin and serotonin were measured by the Luminex method, using the commercial Luminex Human Discovery Assay kit. The average age of the patients was 62.99 years. The level of β-endorphin significantly differs among patients diagnosed with ovarian cancer and among patients in the control group (202.86; SD-15.78 vs. 302.00; SD-24.49). A lower level of β-endorphins was found in the patients with a recurrence of the neoplastic process compared to those without recurrence (178.84; SD-12.98 vs. 205.66; SD-13.37). On the other hand, the level of serotonin before chemotherapy was higher in the group of people with disease recurrence compared to those without recurrence (141.53; SD-15.33 vs. 134.99; SD-10.08). Statistically significantly positive correlations were found between the level of β-endorphin and both disease-free time (β-endorphin levels before chemotherapy: rho Spearman 0.379, < 0.027; β-endorphin levels after chemotherapy: rho Spearman 0.734 < 0.001) and survival time (β-endorphin levels before chemotherapy: rho Spearman 0.267, < 0.018; β-endorphin levels after chemotherapy: rho Spearman 0.654 < 0.001). 1. The levels of serotonin and β-endorphin levels are significantly related to ovarian cancer and change during treatment. 2. High mean preoperative concentrations of β-endorphins were significantly related to overall survival and disease-free time.
本研究旨在评估β-内啡肽和 5-羟色胺对卵巢癌患者治疗过程、无病时间和总生存期的影响。这项研究可能有助于确定可能影响卵巢癌治疗的可改变因素。研究在 162 名患者中进行,其中 139 名患者纳入研究,这些患者中 78 人被诊断为卵巢癌。研究分为三个阶段。在诊断的第一阶段,对患者进行了一项调查。在第二阶段,在术前从每位患者(共 139 人)采集 5 毫升血液,以确定β-内啡肽和 5-羟色胺的浓度。在第三阶段,对已完成化疗或手术的患者采集血样。采用 Luminex 方法,使用商业的 Luminex Human Discovery Assay 试剂盒,测量 β-内啡肽和 5-羟色胺的浓度。患者的平均年龄为 62.99 岁。诊断为卵巢癌的患者和对照组患者的β-内啡肽水平差异显著(202.86;SD-15.78 与 302.00;SD-24.49)。与无肿瘤复发患者相比,肿瘤复发患者的β-内啡肽水平较低(178.84;SD-12.98 与 205.66;SD-13.37)。另一方面,与无疾病复发患者相比,疾病复发患者的化疗前血清 5-羟色胺水平较高(141.53;SD-15.33 与 134.99;SD-10.08)。化疗前β-内啡肽水平与无病时间(化疗前β-内啡肽水平:Spearman rho 0.379,<0.027;化疗后β-内啡肽水平:Spearman rho 0.734,<0.001)和生存时间(化疗前β-内啡肽水平:Spearman rho 0.267,<0.018;化疗后β-内啡肽水平:Spearman rho 0.654,<0.001)呈统计学显著正相关。1. 5-羟色胺和β-内啡肽水平与卵巢癌显著相关,并在治疗过程中发生变化。2. 术前β-内啡肽的平均浓度较高与总生存期和无病时间显著相关。